Neurodevelopmental disorders involve a malfunction of the brain and nervous system. They are generally associated with devastating symptoms that can include seizures and epilepsy, delayed development, difficulties with language and speech, impaired motor skills and behavioral problems, among other symptoms. In many cases, a diagnosis is not confirmed until symptoms become obvious or severe. Treatments, when available, typically involve a combination of physical and behavioral therapies, drugs, and home/school-based support.

In some cases, neurodevelopmental disorders are associated with a dysfunctional receptor known as NMDA. In the brain, NMDA receptors help regulate different physiological functions, including learning and memory. When these receptors are dysfunctional, neurodevelopmental syndromes can emerge with symptoms that include seizures, intellectual disabilities, and neurobehavioral symptoms. The ability to precisely control the activity of NMDA receptors could play a role in the treatment of a range of neurodevelopmental disorders. Radiprodil, an investigational oral selective modulator of the NR2B sub-unit of the NMDA receptor, is currently being developed by GRIN Therapeutics for the potential treatment of GRIN-related disorders as well as TSC and FCD.